Advances and Progress in Drug Design - SMi's ninth annual meeting.
SMi's Advances and Progress in Drug Design, held in London, included topics covering new developments in the field of drug design. This conference report highlights selected presentations on targeting GPCRs and kinases, virtual screening for hit and lead identification, and the ChEMBL database for drug discovery. One investigational drug, losmapimod (GlaxoSmithKline plc), was discussed.
Welchman
Rebecca
R
Thomson Reuters, 77 Hatton Garden, London, UK. rebecca.welchman@thomsonreuters.com
D001185:Artificial Intelligence; D016208:Databases, Factual; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis / Q000737:chemistry; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D011494:Protein Kinases / Q000737:chemistry; D055550:Protein Stability; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry; D012984:Software; D014584:User-Computer Interface; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry
D004364:Pharmaceutical Preparations; D047428:Protein Kinase Inhibitors; D043562:Receptors, G-Protein-Coupled; D011494:Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases